Skip to content
AnalystLens

Roivant Sciences 8-K Report, Material Agreement (May 30, 2024)

Reports
Material Agreements
Filing Date
Filed May 30, 2024
Period End
May 24, 2024
Security
ROIV
In the record · 2021–202610-K510-Q168-K82

ROIV filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 82 current reports (8-K) between 2021 and 2026.

  1. Leadership change8-K · Oct ’21Oct ’21
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Deal closed8-K · Dec ’23Dec ’23
  4. Material agreement8-K · Mar ’26Mar ’26

01—Abstract

Summary

Summary of the 8-K filed May 30, 2024. Cited figures are marked; the original filing is the authoritative source.

On May 24, 2024, Dermavant Sciences Ltd. (DSL), a subsidiary of Roivant Sciences Ltd., entered into a series of agreements to renegotiate its existing debt obligations (the "Debt Renegotiation").

The company states the renegotiation is expected to reduce DSL's potential cash payments under these obligations by over $300 milliona in aggregate, of which approximately $225 million would be achieved over the next three fiscal years. The renegotiation involves amendments to the Revenue Interest Purchase and Sale Agreement (RIPSA), the Credit Agreement, and the NovaQuest Funding Agreement. As part of the transaction, Roivant agreed under an Equity Commitment Letter to contribute $195 million to DSL in exchange for convertible preferred shares with a liquidation preference of 1.5 times its invested capital.

DSL also issued common shares to the RIPSA Purchasers and NovaQuest, each in an amount equal to approximately 13.2% of DSL's issued and outstanding common and preferred shares on an as-converted basis. At closing, and after full funding of the $195 millionb commitment, Roivant will own approximately 87% of DSL's issued and outstanding common and preferred shares and approximately 82% on a fully-diluted basis.

The amendments include a cap of $6 millionc per fiscal year on RIPSA royalties for fiscal years ended March 31, 2025, 2026 and 2027; an extension of the Credit Agreement maturity from May 2026 to May 2028, with the interest rate rising from 10% to 12.25% per annum; and elimination of $176.3 million in fixed quarterly payments tied to tapinarof approval for atopic dermatitis, elimination of up to $141.0 million in commercial milestone payments, and restructuring of remaining NovaQuest payments totaling $122.5 million through fiscal 2029. The full amendments will be filed as exhibits to Roivant's next Form 10-Q.

02—Key points

Key Highlights

  1. Debt Renegotiation at Dermavant Sciences Ltd. (DSL) is expected to reduce potential cash payments by over $300 million in aggregate, with approximately $225 million achieved over the next three fiscal years.
  2. Roivant will contribute $195 million to DSL in exchange for convertible preferred shares with a liquidation preference of 1.5 times invested capital.
  3. Post-closing and after full funding of the $195 million commitment, Roivant will own approximately 87% of DSL's issued and outstanding common and preferred shares and approximately 82% on a fully-diluted basis.
  4. RIPSA royalties are capped at $6 million per fiscal year for fiscal years ending March 31, 2025, 2026 and 2027; the underlying royalty structure (capped at $344 million) is otherwise unchanged.
  5. Credit Agreement maturity extended from May 2026 to May 2028, with the interest rate increasing from 10% to 12.25% per annum and a tiered prepayment premium schedule.
  6. NovaQuest Agreement amended to eliminate $176.3 million in fixed quarterly payments tied to tapinarof approval in atopic dermatitis and up to $141.0 million in commercial milestone payments; remaining payments of $122.5 million are re-timed through fiscal 2029.
  7. The RIPSA Purchasers and NovaQuest each received common shares equal to approximately 13.2% of DSL's issued and outstanding shares on an as-converted basis, including antidilution top-up rights tied to Roivant's equity commitment.

03—Questions

Frequently Asked Questions

  1. What is the Debt Renegotiation and what does it aim to achieve?

    The Debt Renegotiation is a series of agreements by Dermavant Sciences Ltd. to renegotiate its existing debt obligations, aiming to reduce its potential cash payments by over $300 million in aggregate, with an expected reduction of approximately $225 million over the next three fiscal years.

  2. How much will Roivant invest and what will it receive in return?

    Roivant agreed under an Equity Commitment Letter to contribute $195 million to DSL in exchange for DSL issuing Roivant convertible preferred shares with a liquidation preference equal to 1.5 times its invested capital.

  3. How will ownership of Dermavant change?

    The RIPSA Purchasers and NovaQuest each received common shares equal to approximately 13.2% of DSL's issued and outstanding common and preferred shares (as-converted). After the full $195 million funding, Roivant will own approximately 87% of issued and outstanding shares and approximately 82% on a fully-diluted basis.

  4. What changes were made to the Credit Agreement?

    The maturity was extended from May 2026 to May 2028 and the interest rate increased from 10% to 12.25% per annum. Prepayment is permitted with a premium of 5.0% until May 2026, 2.5% from May 2026 to May 2027, and no premium from May 2027 through maturity, with an additional treasury-based make-whole component through May 2025 (except in a change of control).

  5. What are the full terms of the amendments and where can they be found?

    The filing describes the amendments in summary form only. The full text of the RIPSA Amendment, Credit Agreement Amendment and NovaQuest Agreement Amendment will be filed as exhibits to Roivant's next quarterly report on Form 10-Q with the SEC.

04—Continue

← View all 8-K filings